This inventor holds 1 USPTO granted patent and 4 published patent applications. Top assignee: Systimmune, Inc.. Active years: 2026.
Company Filing History:
Years Active: 2026
Title: Gangrui Li: Innovator in Antibody-Drug Conjugates
Introduction
Gangrui Li is a prominent inventor based in Chengdu, China. He has made significant contributions to the field of biopharmaceuticals, particularly in the development of innovative drug conjugates. His work focuses on enhancing the efficacy of cancer treatments through advanced therapeutic strategies.
Latest Patents
Gangrui Li holds a patent for a bispecific antibody-camptothecin drug conjugate, which is aimed at improving pharmaceutical applications in cancer therapy. This innovative approach combines the targeting capabilities of bispecific antibodies with the potent effects of camptothecin, a well-known chemotherapeutic agent. The patent showcases his commitment to advancing medical science and improving patient outcomes.
Career Highlights
Li is currently employed at Systimmune, Inc., where he continues to push the boundaries of drug development. His work at the company has positioned him as a key player in the biopharmaceutical industry. With a focus on creating effective therapies, he has contributed to the advancement of targeted treatments for various diseases.
Collaborations
Throughout his career, Gangrui Li has collaborated with notable colleagues, including Weili Wan and Yiying Zhang. These partnerships have fostered a collaborative environment that encourages innovation and the sharing of ideas, ultimately leading to groundbreaking advancements in their field.
Conclusion
Gangrui Li's contributions to the field of biopharmaceuticals, particularly through his patent on bispecific antibody-drug conjugates, highlight his role as an influential inventor. His work at Systimmune, Inc. and collaborations with esteemed colleagues further emphasize his commitment to advancing medical science.